Piper Sandler analyst David Westenberg maintained a Hold rating on Pacific Biosciences (PACB – Research Report) today and set a price target of $9.00. The company’s shares closed yesterday at $7.11.
According to TipRanks, Westenberg is an analyst with an average return of -5.9% and a 36.22% success rate. Westenberg covers the Healthcare sector, focusing on stocks such as Guardant Health, Adaptive Biotechnologies, and Exact Sciences.
In addition to Piper Sandler, Pacific Biosciences also received a Hold from Barclays’s Luke Sergott in a report issued today. However, yesterday, TD Cowen maintained a Buy rating on Pacific Biosciences (NASDAQ: PACB).
See Insiders’ Hot Stocks on TipRanks >>
PACB market cap is currently $1.78B and has a P/E ratio of -5.56.
Based on the recent corporate insider activity of 22 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of PACB in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Pacific Biosciences (PACB) Company Description:
Pacific Biosciences of California, Inc. engages in the development, manufacture and sale of an integrated platform for genetic analysis. Its products and services include PacBio sequel system, consumables, analytical software, and single molecule real-time (SMRT) compatible products. It operates through the following geographical segments: North America, Europe, and Asia Pacific. The company was founded by Stephen Turner and Joseph Vincent Bonventre on July 14, 2000 and is headquartered in Menlo Park, CA.
Read More on PACB:
